Clarisa R. Gracia

Clarisa R. Gracia

Auto-generated profile, based on publicly available information

Clarisa R. Gracia

Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, University of Pennsylvania, Philadelphia, Pennsylvania

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 December 2018 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
PDF file
KCKatherine Cameron
Katherine Cameron
MSMary Sammel
Mary Sammel
MPMaureen Prewitt
Maureen Prewitt
CGClarisa Gracia
Clarisa Gracia
Context Recent studies have examined level and rate of change of anti-mullerian hormone (AMH) for predicting time to menopause. Limited prospective, longitudinal data exists evaluating measures of ovarian reserve (MOR) in cancer survivors. Purpose Determine the rate of change of MOR in survivors (15-39 years) compared to similar-aged controls and compared to late reproductive-aged controls (40-50 years). Design Prospective cohort Setting Quaternary university hospital Participants Survivors at least 1 year from therapy completion, similar-aged controls, and late reproductive-aged controls. Interventions Annual visits with early follicular-phase hormone analysis and ultrasound. Main Outcome Measure Changes in AMH and antral follicle count (AFC) were modeled using random effects linear regression. Results 170 cancer survivors and 135 similar-aged controls had annual visits for an average of 38 months, while 71 late-reproductive aged controls were followed for an average of 24 months. In models adjusted for body mass index, time since cancer therapy (for survivors), and exogenous hormone use, the geometric mean AMH and AFC levels were lower in the survivors than similar-aged controls at all ages. After age 24.5 AMH and AFC declined in both groups at rates that were similar (p=0.78 for AMH, p=0.37 for AFC). Late-reproductive aged controls declined at a much more precipitous rate of 30% per year for AMH and 16% per year for AFC (p<0.01 compared to survivors). Conclusions Though survivors had lower levels of AMH and AFC at the time of enrollment, the rate of change of AMH and AFC is not significantly different than similar-aged controls.

21 May 2014 in Journal of Adolescent and Young Adult Oncology
Verified
Journal Article
Open access
NLNataniel H. Lester-Coll
Nataniel H. Lester-Coll
CMChristopher B. Morse
Christopher B. Morse
HZHuifang A. Zhai
Huifang A. Zhai
SBStefan Both
Stefan Both
JGJill P. Ginsberg
Jill P. Ginsberg
CHChristine E. Hill-Kayser
Christine E. Hill-Kayser
Craniospinal irradiation (CSI) is associated with infertility risk for adolescent/young adult women. We explore two methods of reducing ovarian exposure: oophoropexy (surgical removal of the ovaries from the path of the X-ray beam) and proton therapy (to allow the beam to stop without exposing the ovaries/uterus). In the case discussed, oophoropexy followed by X-ray CSI reduced ovarian dose to that at which 50% of oocytes are expected to survive, and the patient appears to have viable oocytes; this technique did not reduce uterine dose. Proton therapy would have eliminated the ovarian and uterine dose and the need for oophoropexy.

7 October 2013 in Seminars in Reproductive Medicine
Verified
Journal Article
Closed access
KDKatherine E. Dillon
Katherine E. Dillon
CGClarisa R. Gracia
Clarisa R. Gracia
While hormonal and ultrasonographic measures of ovarian reserve are often used to counsel patients about their fertility potential, normative data for these markers in the general population are lacking. Most studies are cross sectional and take place within specific subpopulations. Antral follicle count and anti-Mullerian hormone have been shown to be the best indicators of a woman's total follicular reserve. Ovarian volume, inhibin B, estradiol, and follicle-stimulating hormone are less helpful. Antral follicle count and anti-Mullerian hormone decrease with age and have been used to attempt to predict the length of the fertile window. Additional longitudinal data are needed for these biomarkers in populations of young, healthy, multiethnic women to assess for the presence of cofactors and determine the rate of age-related decline. Currently, these biomarkers are insufficient as predictors of fertility potential or advancement to menopause and no definitive determinations can be made about what constitutes “normal” levels of each measure.

30 September 2002 in Fertility and Sterility
Verified
Journal Article
Closed access
GKGeorge Kovalevsky
George Kovalevsky
CGClarisa Gracia
Clarisa Gracia
JBJesse A Berlin
Jesse A Berlin
MSMary Dupuis Sammel
Mary Dupuis Sammel
KBKurt Thomas Barnhart
Kurt Thomas Barnhart

1 September 2002 in Fertility and Sterility
Verified
Journal Article
Closed access
PDF file
CGClarisa R Gracia
Clarisa R Gracia
MSMary Sammel
Mary Sammel
LLLi Liu
Li Liu
LHLori Hollander
Lori Hollander
EFEllen W Freeman
Ellen W Freeman